ABEONA THERAPEUTICS INC. 8-K

What Happened

• Abeona Therapeutics, Inc. held a virtual annual meeting of stockholders on June 12, 2026 (9:00 a.m. ET) and reported the voting results in an 8-K. Two directors — Keith A. Goldan and Bernhardt G. Zeiher, M.D. — were elected as Class 1 directors to serve until the 2029 annual meeting and until their successors are elected and qualified.
• Other shareholder votes included a non-binding advisory "say-on-pay" approval of executive compensation, ratification of Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal 2026, approval to increase shares reserved under the 2023 Equity Incentive Plan, and a failed proposal to remove the advance notice provision for director nominations from the charter.

Key Details

• Directors elected:
  • Keith A. Goldan — For: 28,305,958; Against: 1,352,589; Abstentions: 70,514; Broker Non-Votes: 12,256,230.
  • Bernhardt G. Zeiher, M.D. — For: 28,131,990; Against: 1,577,444; Abstentions: 19,627; Broker Non-Votes: 12,256,230.
• Advisory vote on executive compensation (say-on-pay): For 23,300,653; Against 4,511,866; Abstentions 1,916,542; Broker Non-Votes 12,256,230 (approved).
• Auditor ratification: Deloitte & Touche LLP ratified — For 40,560,995; Against 1,381,486; Abstentions 42,810.
• Equity plan increase approved: increase reserved shares from 8,400,000 to 11,500,000 — For 23,975,061; Against 5,720,643; Abstentions 33,357; Broker Non-Votes 12,256,230.
• Charter amendment to remove advance notice provision was not approved (failed to meet required ≥66 2/3%): For 24,559,006; Against 4,667,640; Abstentions 502,415; Broker Non-Votes 12,256,230.

Why It Matters

• Board continuity: Election of two Class 1 directors maintains board composition through the 2029 meeting, affecting governance and oversight.
• Shareholder sentiment: The advisory approval of executive compensation signals shareholder support for pay practices, though the vote is non-binding.
• Capital allocation and dilution: Approval to increase shares under the 2023 Equity Incentive Plan expands the pool available for future equity grants to employees and directors, which can affect share dilution over time.
• Governance rules unchanged: Failure to remove the advance notice requirement means the current director nomination process in the charter remains in place, preserving existing nomination procedures.